DaVita HealthCare Partners is trading 4.5% down at $217.80 in pre-market, extending a two-day slide following its August 4, 2026 earnings release.
- While the company beat Q2 revenue and EPS expectations on efficiency gains, management only reiterated full-year guidance, which has limited further upside for the stock.
- Investors appear to be pricing in concerns regarding muted patient volume growth, triggering post-earnings profit-taking despite the bottom-line beat.